Abstract OBJECTIVE In the Evaluate Renal Function With Semaglutide Once Weekly (FLOW) trial, semaglutide reduced the risk of major kidney and cardiovascular (CV) outcomes and all-cause mortality in people with type 2 diabetes (T2D) and chronic kidney disease (CKD)
Debido a la rpida reduccin de la hemoglobina glucosilada, un valor que indica si el metabolismo de la glucosa funciona mejor o peor
Any hospital that is assigned 5 stars in step eight but has a lowest quartile Safety of Care score (based on at least three Safety of Care measures) would be reassigned to 4 stars
Not just more GLP-1 but more choice: oral, higher dose, and combination biologyeach built for different patients
More comprehensive monitoring would add fasting glucose, HbA1c, liver enzymes, and lipid panel testing at baseline and regular intervals
Svane MS, Jorgensen NB, Bojsen-Moller KN et al (2016) Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery